Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Total Current Liabilities (2016 - 2026)

Gyre Therapeutics has reported Total Current Liabilities over the past 16 years, most recently at $18.3 million for Q4 2025.

  • Quarterly Total Current Liabilities fell 6.3% to $18.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $18.3 million through Dec 2025, down 6.3% year-over-year, with the annual reading at $18.3 million for FY2025, 6.3% down from the prior year.
  • Total Current Liabilities was $18.3 million for Q4 2025 at Gyre Therapeutics, up from $15.9 million in the prior quarter.
  • Over five years, Total Current Liabilities peaked at $20.0 million in Q4 2023 and troughed at $1.6 million in Q3 2022.
  • The 5-year median for Total Current Liabilities is $15.1 million (2021), against an average of $13.2 million.
  • Year-over-year, Total Current Liabilities tumbled 90.47% in 2022 and then surged 725.35% in 2024.
  • A 5-year view of Total Current Liabilities shows it stood at $14.2 million in 2021, then dropped by 13.58% to $12.2 million in 2022, then skyrocketed by 63.76% to $20.0 million in 2023, then decreased by 2.65% to $19.5 million in 2024, then dropped by 6.3% to $18.3 million in 2025.
  • Per Business Quant, the three most recent readings for GYRE's Total Current Liabilities are $18.3 million (Q4 2025), $15.9 million (Q3 2025), and $16.9 million (Q2 2025).